Association for Molecular Pathology


June 2011, Volume 17, Number 2


Inside this Issue

Front Page
President's Message
Special Features
The Journal of Molecular Diagnostics
Web Editorial Board
Committee Reports
Clinical Practice Committee
Economic Affairs Committee
Membership and Professional Development Committee
Nominating Committee
Professional Relations Committee
Program Committee
Training & Education Committee
Officers, Appointees and Staff
2011 AMP Officers and Appointees
This Newsletter is published three times a year by the Association for Molecular Pathology (AMP). The contents of the Newsletter may not be reproduced for distribution of any kind without the express, specific, written permission of the association. AMP will not publish and/or post material that is primarily commercial in nature. Articles, announcements, and news briefs are welcome and will be edited and published at the discretion of the editors. Copyright 2011, Association for Molecular Pathology.

Teresita Cuyegkeng Redondo, MD
Marlene Sabbath-Solitare, PhD
Production Editor:
Alta E. Wallington
AMP Logo
Association for Molecular Pathology
9650 Rockville Pike, Suite E133
Bethesda, MD 20814-3993
Tel: 301-634-7939, Fax: 301-634-7990

President's Message

Timothy J. O'Leary, MD, PhD

By Timothy J. O'Leary, MD, PhD

The AMP position on gene patents and the legal position it has taken with regard to these patents has polarized the membership more, perhaps, than any other issue in this organization’s history. Although it is possibly true that members representing “for-profit” commercial organizations favoring the patentability of gene sequence information are disproportionately represented, there are members from industry who stand to gain if gene patents are disallowed and from academic institutions who will lose revenue if gene sequences are found to be non-patentable. Although it may be several years before we know the answer, on April 4, 2011 the Court of Appeals for the Federal Circuit (CAFC) heard oral arguments on Myriad Genetics’ appeal of the decision invalidating its BRCA1 and BRCA2 sequence patents.  >>Read the Article

2011 Recipient of AMP Leadership Award

Peggy GulleyThe AMP Leadership Award, supported by an unrestricted educational grant from Abbott Molecular, is bestowed each year during the Business and Awards Session of the Annual Meeting to an AMP member who has demonstrated exceptional leadership in the accomplishment of the mission and goals of AMP. This year’s Award recipient is Margaret L. Gulley, MD.

Dr. Gulley is a Professor in the Department of Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill; her laboratory is noted for its work in EBV-related malignancies. “Peggy” has been a member of AMP since its formation. At the “Molecular Diagnostics Workshop,” held in Bethesda, Maryland in November 1994, organizers taped large sheets of paper to the wall and asked people to sign up to serve on committees to develop the structure of a new organization dedicated to molecular pathology. Peggy signed up for several committees and thus was present at AMP’s birth. Her dedication to the molecular pathology profession and to AMP has been tireless. She became AMP’s President in 1997 and has been a familiar presence at our Annual Meetings, on CHAMP and as a member of the faculty for the AMP Molecular Genetic Pathology Review Course.

Come congratulate Peggy as she receives this award during the Business and Awards Session at the AMP 2011 Annual Meeting in Grapevine (near Dallas), Texas.